Aflibercept 8mg for high-frequent Faricimab and prior Aflibercept 2mg treated Neovascular age-related macular degeneration: a monocenter, single-arm, open-label extension study (A-FAN)
This research study, called A-FAN, is investigating a medicine called aflibercept 8mg for people with wet age-related macular degeneration (wet AMD). This is a condition that affects your eyesight. The study focuses on participants who have previously received other treatments like aflibercept 2mg or faricimab. The main goal is to see how many people can go for longer periods between their eye injections without fluid building up in their retina, which is a sign the treatment isn't working as well. Researchers will also look at how much eyesight improves and if the new treatment schedule is safe and effective. It's an open-label study, meaning participants and doctors know which treatment is being given.
At a glance
What is this study about?
This study is about a common eye condition called wet age-related macular degeneration, or wet AMD. This condition can lead to blurry vision or blind spots because abnormal blood vessels grow under the central part of your retina (the back of your eye) and leak fluid or blood. Treatments often involve regular injections into the eye to stop this leakage and protect your vision.
The A-FAN study is specifically looking at a higher dose of an existing medicine, aflibercept (8mg), to see if it can help people who have already been treated with other similar medicines, like aflibercept (2mg) or faricimab. The main idea is to find out if this stronger dose allows people to have fewer injections, by extending the time between each treatment, while still keeping their eye condition under control. This could make managing wet AMD much easier for patients.
Researchers will be carefully checking if the fluid in the eye goes away or stays gone for longer periods between injections. They will also measure changes in vision and keep a close eye on any side effects. This study is important because finding ways to reduce the number of injections could greatly improve the quality of life for people living with wet AMD, making their treatment journey more manageable.
Key takeaways
- A-FAN is studying a new way to use aflibercept 8mg for wet AMD.
- It aims to see if patients can have fewer eye injections while maintaining good vision control.
- The study is for people who have already been treated with other wet AMD medicines.
- Patients will receive injections over about 32 weeks, with close monitoring.
- The goal is a better, more convenient treatment schedule for wet AMD patients.
Who may be eligible?
To be considered for this study, you must be an adult, aged 18 or older, and can be male or female. The study is for people who have been diagnosed with wet age-related macular degeneration, the 'wet' form of AMD.
You would also need to have received previous treatments for your wet AMD. Specifically, this study is looking for people who have had injections of aflibercept 2mg or faricimab before joining. This is because the study wants to see how a new dose of aflibercept works for people who have already been through standard treatments.
Other specific medical details will be checked by the study doctor to make sure it's safe and appropriate for you to participate. This ensures the study gathers useful information and protects the health of everyone involved.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with wet age-related macular degeneration (wet AMD)?
- Have you previously received eye injections for wet AMD with aflibercept 2mg or faricimab?
- Are you able to attend regularly scheduled clinic appointments for eye injections and check-ups?
What does participation involve?
If you decide to join this study, you will receive injections of aflibercept 8mg into your eye over a period of 32 weeks, which is about 8 months. Initially, you might have injections more frequently, and then the doctors will try to extend the time between your visits if your eye condition remains stable.
You will have several appointments at the study clinic during these 32 weeks. These visits will involve eye examinations, vision tests (like reading letters on a chart), and scans of your eye to check for fluid. Some visits may also include blood tests. The exact number of injections and visits will depend on how your eye responds to the treatment. The goal is to find the longest possible time between injections for you where your eye condition remains stable.
Throughout the study, the medical team will monitor your general health and any possible side effects very closely. After the 32 weeks, there might be a final follow-up visit. The total duration of your active participation will be around 8 months, but the specific schedule will be explained in detail by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedAustria
Common questions
What is wet AMD?
Wet AMD is an eye condition where abnormal blood vessels grow in your eye and leak fluid, causing blurry vision or blind spots.
What is aflibercept 8mg?
Aflibercept 8mg is a medicine given by injection into the eye, and this study is testing if a higher dose can help reduce the frequency of injections for wet AMD.
How long will the study last for me?
Your active participation in the study will last for approximately 32 weeks, which is about 8 months.
Will I know if I'm getting the study drug?
Yes, this is an 'open-label' study, meaning both you and your doctor will know you are receiving aflibercept 8mg injections.
Can I stop participating in the study if I change my mind?
Yes, you can choose to leave the study at any time, for any reason, without affecting your usual medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.